3.74
price up icon3.17%   0.115
after-market Dopo l'orario di chiusura: 3.64 -0.10 -2.67%
loading
Precedente Chiudi:
$3.625
Aprire:
$3.65
Volume 24 ore:
286.95K
Relative Volume:
0.73
Capitalizzazione di mercato:
$275.57M
Reddito:
$351.37M
Utile/perdita netta:
$-174.01M
Rapporto P/E:
-1.8068
EPS:
-2.07
Flusso di cassa netto:
$-126.94M
1 W Prestazione:
+5.95%
1M Prestazione:
+16.15%
6M Prestazione:
+6.25%
1 anno Prestazione:
+14.02%
Intervallo 1D:
Value
$3.65
$3.7599
Intervallo di 1 settimana:
Value
$3.425
$3.80
Portata 52W:
Value
$2.455
$4.145

Atea Pharmaceuticals Inc Stock (AVIR) Company Profile

Name
Nome
Atea Pharmaceuticals Inc
Name
Telefono
857-204-8109
Name
Indirizzo
225 FRANKLIN STREET, BOSTON
Name
Dipendente
56
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
AVIR's Discussions on Twitter

Confronta AVIR con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
AVIR
Atea Pharmaceuticals Inc
3.74 275.57M 351.37M -174.01M -126.94M -2.07
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.62 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.36 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.91 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
543.48 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.49 28.51B 3.81B -644.79M -669.77M -6.24

Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-08-13 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2023-08-10 Downgrade JP Morgan Neutral → Underweight
2022-01-06 Downgrade Morgan Stanley Equal-Weight → Underweight
2021-11-18 Downgrade SVB Leerink Outperform → Mkt Perform
2021-10-20 Downgrade JP Morgan Overweight → Neutral
2021-10-05 Downgrade Morgan Stanley Overweight → Equal-Weight
2020-11-25 Iniziato Evercore ISI Outperform
2020-11-24 Iniziato JP Morgan Overweight
2020-11-24 Iniziato Morgan Stanley Overweight
2020-11-24 Iniziato William Blair Outperform
Mostra tutto

Atea Pharmaceuticals Inc Borsa (AVIR) Ultime notizie

pulisher
Jun 17, 2025

Here's Why We're Not At All Concerned With Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Situation - Yahoo Finance

Jun 17, 2025
pulisher
Jun 15, 2025

Bank of America Corp DE Boosts Stock Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Jun 15, 2025
pulisher
Jun 14, 2025

Millennium Management LLC Invests $75,000 in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Jun 14, 2025
pulisher
Jun 09, 2025

Squarepoint Ops LLC Buys 35,053 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Jun 09, 2025
pulisher
Jun 07, 2025

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Two Sigma Investments LP - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

Jane Street Group LLC Decreases Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Public Employees Retirement System of Ohio Trims Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Ameriprise Financial Inc. Sells 11,900 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Jun 06, 2025
pulisher
Jun 04, 2025

ProShare Advisors LLC Buys 6,163 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Jun 04, 2025
pulisher
Jun 02, 2025

Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace

Jun 02, 2025
pulisher
May 27, 2025

BNP Paribas Financial Markets Buys New Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

May 27, 2025
pulisher
May 26, 2025

Northern Trust Corp Boosts Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

May 26, 2025
pulisher
May 24, 2025

D. E. Shaw & Co. Inc. Purchases 62,505 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

May 24, 2025
pulisher
May 24, 2025

Wall Street Zen Upgrades Atea Pharmaceuticals (NASDAQ:AVIR) to “Hold” - Defense World

May 24, 2025
pulisher
May 17, 2025

Price T Rowe Associates Inc. MD Purchases 3,882 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

May 17, 2025
pulisher
May 16, 2025

Q2 EPS Forecast for Atea Pharmaceuticals Reduced by Analyst - Defense World

May 16, 2025
pulisher
May 14, 2025

Dimensional Fund Advisors LP Has $3.27 Million Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

May 14, 2025
pulisher
May 14, 2025

Transcript : Atea Pharmaceuticals, Inc.Special Call - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Atea Pharmaceuticals Advances HCV Treatment Trials - TipRanks

May 14, 2025
pulisher
May 12, 2025

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

May 12, 2025
pulisher
May 10, 2025

Wells Fargo & Company MN Increases Stock Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

May 10, 2025
pulisher
May 10, 2025

Atea Pharmaceuticals (AVIR) to Release Earnings on Monday - Defense World

May 10, 2025
pulisher
May 08, 2025

Atea reports high efficacy in Phase 2 HCV drug trial By Investing.com - Investing.com Nigeria

May 08, 2025
pulisher
May 08, 2025

Barclays PLC Increases Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

May 08, 2025
pulisher
May 07, 2025

Atea Pharmaceuticals (AVIR) Reveals Promising Phase 2 Results for Hepatitis C Treatment | AVIR Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Atea reports high efficacy in Phase 2 HCV drug trial - Investing.com

May 07, 2025
pulisher
May 07, 2025

Atea Pharmaceuticals Announces Full Results from Phase 2 - GlobeNewswire

May 07, 2025
pulisher
May 07, 2025

Atea Pharmaceuticals Announces Full Results From Phase 2 Study Of Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus (HCV) Presented At EASL Congress 2025 - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025 - Stock Titan

May 07, 2025
pulisher
May 01, 2025

A stock that deserves closer examination: Atea Pharmaceuticals Inc (AVIR) - uspostnews.com

May 01, 2025
pulisher
May 01, 2025

Atea Pharmaceuticals (AVIR) Organizes HCV Treatment Panel & Announces Q1 Results | AVIR Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 - The Manila Times

May 01, 2025
pulisher
Apr 26, 2025

JPMorgan Chase & Co. Buys 314,015 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Apr 26, 2025
pulisher
Apr 26, 2025

Geode Capital Management LLC Lowers Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Apr 26, 2025
pulisher
Apr 25, 2025

Atea Pharmaceuticals Inc (AVIR) produces promising results - uspostnews.com

Apr 25, 2025
pulisher
Apr 25, 2025

Financial Health Report: Atea Pharmaceuticals Inc (AVIR)’s Ratios Tell a Tale - DWinneX

Apr 25, 2025
pulisher
Apr 23, 2025

Atea Pharmaceuticals (AVIR) to Reveal Phase 2 Study Results at E - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 - GlobeNewswire

Apr 23, 2025
pulisher
Apr 23, 2025

AVIRAtea Pharmaceuticals, Inc. Latest Stock News & Market Updates - Stock Titan

Apr 23, 2025
pulisher
Apr 22, 2025

A better buy-in window may exist right now for Atea Pharmaceuticals Inc (AVIR) - Sete News

Apr 22, 2025
pulisher
Apr 18, 2025

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Vanguard Group Inc. - Defense World

Apr 18, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals expands board, authorizes stock buyback By Investing.com - Investing.com Canada

Apr 17, 2025
pulisher
Apr 17, 2025

Latham & Watkins Advises Atea Pharmaceuticals in Agreement With Radoff-JEC Group - Latham & Watkins LLP

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Appoints Howard H. Berman To Board - citybiz

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Announces Board Changes and Share Buyback - TipRanks

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Board Approves $25 Million Share Repurchase Program - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals expands board, authorizes stock buyback - Investing.com

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals says strategic alternatives process ‘ongoing’ - TipRanks

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Appoints Howard H. Berman To Board Of Directors And Announces Share Repurchase Program - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program - GlobeNewswire

Apr 17, 2025

Atea Pharmaceuticals Inc Azioni (AVIR) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Atea Pharmaceuticals Inc Azioni (AVIR) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
BERGER FRANKLIN M
Director
Jun 20 '25
Option Exercise
0.00
29,600
0
506,497
Duncan Barbara Gayle
Director
Jun 20 '25
Option Exercise
0.00
29,600
0
62,750
Polsky Bruce
Director
Jun 20 '25
Option Exercise
0.00
29,600
0
95,206
Adams Jerome M.
Director
Jun 20 '25
Option Exercise
0.00
29,600
0
62,750
Lucidi Bruno
Director
Jun 20 '25
Option Exercise
0.00
29,600
0
112,750
BERGER FRANKLIN M
Director
Dec 10 '24
Sale
2.85
359,606
1,023,475
451,897
$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
Capitalizzazione:     |  Volume (24 ore):